Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1234 - Radiologic feature after chemotherapy with anti-VEGF drug for CLM


19 Dec 2015


Poster presentation 1


Hitoshi Fujii


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


H. Fujii1, T. Ito2, H. Kin2, I. Mitsunobu2, A. Hayashibe3, H. Ikushima3, Y. Fumimoto3, N. Ogino3

Author affiliations

  • 1 Surgery, Tondabayashi hospital, 5840082 - Tondabayashi/JP
  • 2 Surgery, Rinku General Medical Center, izumisano/JP
  • 3 Surgery, Tondabayashi hospital, Tondabayashi/JP


Abstract 1234


It was reported that novel criteria based on morphologic changes observed on computed tomography in patients with colorectal liver metastasies (CLM) undergoing preoperative chemotherapy and long-term outcomes. The purposes of this study were to confirm the difference of morphologic change to CLM after various chemotherapies.


The study included 38 patients who underwent 5FU-based 1st line regimens with or without molecular target therapy (anti-VEGF drug or anti-EGFR drug) for CLM from 2007 to 2012. They were divided into 3 groups (12 cytotoxic agents alone group, e.g. FOLFOX, XELOX and FOLFIRI, 17 cytotoxic agents with anti-VEGF drug group, and 9 cytotoxic agents with anti-EGFR drug group) retrospectively. All patients underwent routine contrast-enhanced CT at the start of and during chemotherapy. We created a circle to assume 1/4 of the minor axis a radius from the center of a liver tumor, and measured a circular inside CT value of the tumor and an outside CT value and revised the value of erector spinae muscle in a standard. We defined revised inside CT value as Tin, and outside as Tout. Assessment was performed using RECIST.


The rate of response in each group was 33.3%, 58.8%, 66.7%. Two of these 38 patients had a complete response. In comparison with CT before the treatment and the CT 12 weeks after the treatment, eight of 9 responder with anti-VEGF drug showed that the Tin decreased more than 30%, whereas none of 7 non responder with anti-VEGF drug didn't show similar morphologic change (p = 0.0014). The morphologic change that the Tin decreased more than 30% was observed in 88.9 % of response patients with anti-VEGF drug, 25.0% of response patients with cytotoxic agents alone, and 40.0% of response patients with anti-EGFR drug. Though there was no statistically significant difference among the three groups (p = 0.06), these results may in part explain the radiologic feature after chemotherapy with anti-VEGF drug for CLM.


Liver tumor after chemotherapy with anti-VEGF drug may do different morphologic change from the other chemotherapy.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings